Brian Lian - Apr 17, 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role: President & CEO, Director
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Stock symbol: VKTX
Transactions as of: Apr 17, 2023
Transactions value $: -$2,901,016
Form type: 4
Date filed: 4/18/2023, 07:09 PM
Previous filing: Apr 13, 2023
Next filing: Apr 21, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VKTX	Common Stock, par value $0.00001 per share	Options Exercise	$269K	+125K	+5.42%	$2.15^*	2.43M	Apr 17, 2023	Direct	F1
transaction	VKTX	Common Stock, par value $0.00001 per share	Sale	-$3.17M	-155K	-6.37%	$20.45	2.28M	Apr 17, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VKTX	Stock Option (Right to Buy)	Options Exercise	$0	-125K	-100%	$0.00^*	0	Apr 17, 2023	Common Stock	125K	$2.15	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person.
F2	25% of the shares subject to the option vested on each anniversary of the grant date.